Category: Therapy

Description

This page contains brief details about the drug olaparib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Olaparib is an anticancer medicine referred to as the Poly Adenosine Diphosphate-Ribose Polymerase (PARP) inhibitor. It was approved for its medical use on 19th December 2014.

Mechanism of Action of Olaparib

Olaparib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a PARP inhibitor. PARP enzymes facilitate multiple DNA repair pathways and these repair mechanisms lead to the development of cancer cells. These enzymes specifically target cells with mutations in BRCA genes. Olaparib works by inhibiting PARP enzymes blocks repair of single stranded DNA, and ultimately hinders the growth and development of cancer cells. Olaparib is prescribed alone or in combination with other anticancer drugs like bevacizumab.

Uses of Olaparib

Olaparib Tablet has been developed as a maintenance therapy to treat adult patients with cancer in the ovaries, fallopian tube, peritoneum, pancreas, prostate due to BRCA mutation and have completely or partially responded to platinum-based chemotherapy.

Olaparib Dosage available

The recommended dose of Olaparib Tablet is 300mg twice a day with or without food. Olaparib Tablet is available in the doses of 100mg and 150mg and the strength varies according to the patient’s health condition. In patients with kidney impairment, the recommended dose is 200mg twice a day.

Description

This page contains brief details about the drug dasatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Dasatinib is an anticancer agent which was approved for its medical use on 28th June 2006.

Mechanism of Action of Dasatinib

Dasatinib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a tyrosine kinase inhibitor. The BCR ABL tyrosine kinase enzymes are responsible for the uncontrolled generation of white blood cells in leukemia. Dasatinib binds to both active and inactive sites of BCR ABL tyrosine kinase enzyme to inhibit the uncontrolled growth of white blood cells.

Uses of Dasatinib

Dasatinib Tablet has been developed to treat Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia in adults, adolescents and children who have not benefitted from previous therapies. It is also approved for treating chronic myeloid leukemia.

Dasatinib Dosage available

The recommended starting dose for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia is 140 mg per day. The ideal dose for children is calculated based on their body weight.

Dasatinib is available as a tablet in doses 20mg, 50mg, 70mg, and 100mg. It is advisable to take the tablets at the same time each day. Swallow them whole with some water and do not crush, cut or chew them.